Matrix metalloproteinase-1 and -9 promoter polymorphisms are not associated with an increased risk of uterine leiomyomas in a Japanese population

J Soc Gynecol Investig. 2006 Apr;13(3):232-6. doi: 10.1016/j.jsgi.2006.02.004.

Abstract

Objective: Matrix metalloproteinases (MMPs) play an important role in modeling and remodeling the extracellular matrix in leiomyomas. Hence, we investigated whether associations exist between leiomyomas and promoter polymorphisms in the MMP-1 and MMP-9 genes in a Japanese population.

Methods: We compared the distribution of polymorphisms in the promoter regions of MMP-1 (-1607 1G/2G) and MMP-9 (-1562 C/T) in 267 leiomyoma patients and 184 control patients using polymerase chain reaction-fragment-length polymorphism (PCR-RFLP) analysis.

Results: The allele frequencies of the MMP-1 -1607 2G and MMP-9 -1562 T polymorphisms were 74.6% and 18.6% in leiomyoma patients, and 71.3% and 18.6% in control patients, respectively. No significant differences in allele frequencies or genotype distributions were found between leiomyoma and control patients. Moreover, no associations were found between MMP-1 and MMP-9 genotypes and leiomyoma size or a family history of the condition.

Conclusion: These findings suggest that MMP-1 and MMP-9 promoter polymorphisms are unlikely to be associated with an increased risk of uterine leiomyomas in Japanese women.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Extracellular Matrix / metabolism
  • Female
  • Genotype
  • Humans
  • Japan
  • Leiomyoma / enzymology
  • Leiomyoma / genetics*
  • Matrix Metalloproteinase 1 / genetics*
  • Matrix Metalloproteinase 9 / genetics*
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Genetic
  • Polymorphism, Restriction Fragment Length
  • Promoter Regions, Genetic
  • Risk Factors
  • Uterine Neoplasms / enzymology
  • Uterine Neoplasms / genetics*

Substances

  • Matrix Metalloproteinase 9
  • Matrix Metalloproteinase 1